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Summary: The synthesis of tissue factor pathway inhibitor (TFPI) was investigated in cloned human synovial cells
and human chondrocytes. TFPI-specific DNA transcription products of these cells were isolated, and a full-length
cDNA of about 1000 base pairs was amplified by reverse transcription and polymerase chain reaction. The amplified
DNA was cloned into the vector pUC 18. The TFPI coding sequence was confirmed by double stranded sequencing
and was identical with that previously published for human TFPI coding nucleotide sequence frorn human placental
cDNA (1).
The inhibitory activity of TFPI in the cell medium of cultivated human chondrocytes and cloned human synovial
cells was determined by a specific chromogenic Substrate assay of factor Xa activity. The inhibitory activity of
TFPI in the medium of human chondrocytes and cloned human synovial cells was 630-720 mU/108 cells and
1080-1665 mU/108 cells, respectively.
In addition, TFPI activity in cell culture media of human chondrocytes and cloned human synovial cells was
suppressed by a polyclonal goat anti-TFPI antibody directed against the inhibitory domain I and domain II. In
the chromogenic Substrate assay, the anti-TFPl antibody completely suppressed the inhibitory activity of TFPI in
the samples.
Introduction (i) TFPI inhibits factor Xa and (ii) factor Xa/TFPI com-
plex inhibits factor VH/tissue factor complex by forming
Tissue factor pathway inhibitor (TFPI) is a physiplogi- a quaternary complex (3, 4).
cally important factor in blood coagylatiön (1), con-
sisting of three tandem Kunitz-type inhibitor domains.
Domain I has been identified äs the binding site of factor j ^ c t c a ^ EC 3 4 2 1 6
Vlla/tissue factor1). The second domain binds factor Factor Vlla EC 3.4.21.21
Xa1); the function of the third domain is still unclear (2). Reverse transcriptase EC 2.7.7.49
Taq polymerase EC 2.7.4.-
DNA polymerase EC 2.7.7.7
TFPI is involved in the regulation of coagulation by EcoW. EC3.1.21.-
binding to factor Vlla/tissue factor (2). The inhibitory coUagenase EC 3^3!24!3
activity of TFPI occurs in two Steps: Pronase EC 3,4.24.31
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TFP1 has been detected in endothelial cells and mega-
karyocytes. Only minimal amounts are present in
mononuclear cells, and none has been detected in hepa-
tocytes (5). However, the expression of TFPI in cells of
the synovial System has not hitherto been investigated.
It has been suggested that TFPI may be an important
factor for bleeding in haemophiliacs (6) and it has been
shown that blocking of TFPI normalises the dilute tissue
factor clotting time, which is prolonged in plasma of
haemophiliacs (7). Inhibition of coagulation in the syn-
ovial System has been assumed in haemophilia. In this
disease, the alternative factor X activation is not pos-
sible, due to factor VIII or IX deficiency. Haemophilic
patients suffer spontaneous and often massive bleeding,
90% of which occurs in the joints. The predilection of
joint bleeding in haemophiliacs led us to investigate the
expression of tissue factor pathway inhibitor in human
chondrocytes and human synovial cells.
Materials and Methods
Materials
Agarose was purchased frorn Biozyme Diagnostic, Hameln. Dul-
becco's Eagle medium, Harn9s F-12 medium, foetal calf serum,
human factor VII, human factor X, N-benzoyl-Ile-Glu-Gly-Arg-/>-
nitroanilide (S-2222), CsCl and antibiotic and antimycotic solution
were obtained from Sigma, Deisendorf. Recombinant tissue factor
was from Baxter, Unterschlei heim and AmpliTaq DNA Poly-
merase from Perkin Eimer Cetus, Vaterstetten. Reverse tran-
scriptase was obtained from BRL, Eggenstein and DNA Standard
and dNTP were from Pharmacia, Freiburg. Polycarbonate filters
were purchased from Nunc, Wiesbaden. All chemicals used were
of analytical grade or the highest grade commercially available.
phate (9), hyaluronan) and markers specific for macrophages
(neopterin, sCD14) (data not shown).
Preparalion of human chondrocyte cell cultures
Chondrocyte cultures were prepared from pieces of human knee
joints. The pieces were collected in Harn 's F-12 medium, which
was enriched with 10 g/l antibiotic solution (see section cell cul-
ture). Cartilage slices were digested for 90 min at 37 °C with 0.01
g/l pronase in 100 ml F-12 medium containing 5 g/l foetal b vine
serum, followed by 0.3 g/l bacterial collagenase1) in the same me^
dium for 180 min at 37 °C. The final digest was centrifuged at
900s"1 for 10 min. The cell pellet was washed three times in
serum-free medium. The cells were collected by passing the sus-
pension through a Nitex nylon filter (mesh width 60 μιη), then
resuspended in serum-containing medium. Cell viability was deter-
mined by trypan blue dye exclusion. The cells were cultivated over
four days in F-12 medium in tissue culture dishes precoated with
agarose to avoid cell attachment. The surviving chondrocytes were
collected again on a nylon filter and examined under a light micro-
scope for their spherical morphology.
Ribonucleic acid Isolation
The total amount of cellular RNA was isolated by CsCl gradient
centrifugation (11). Cells (lO8 in 10 ml cell culture medium) were
centrifiiged for 10 min at 900 s"1 and the pellet was washed with
10ml buffer (0.14 mol/1 NaCl, 0.0027 mol/1 KC1, 0.008 mol/1
Na2HPO4, 0.0015 mol/1 KH2PO4, 0.0005 mol/1 MgCl2, 0.0009
mol/1 CaCl2, l g/l glucose, pH 7.3). The pellet was resuspended
in l .6 ml guanidinium thiocyanate solution (0.025 mol/1 Tris/HCl,
4 mol/1 guanidinium thiocyanate, 0.5 g/l N-lauroylsarcosine, 0.025
mol/1 EDTA, 0.1 mol/1 -mercaptoethanol, pH 7.6). The solution
was aspirated 10 times through a small syringe needle tp shear
chromosomal DNA. After the addition of CsCl solution (5.7 mol/1
CsCl, 0.01 mol/1 EDTA, pH 7.0) to a final volume of 4.5 ml, the
solution was centrifiiged for 18 hours at 150000s"1. The super-
natant was discarded and the RNA pellet was dissolved in 100 μΐ
0.01 mol/1 Tris, 0.001 mol/1 EDTA, pH 7.4 (10). After phenol ex-
traction and precipitation with ethanol (12) the isolated RNA was
used for cDNA synthesis by reverse transcription.
Methods
Cell culture
Human chondrocytes and human synovial cells were obtained from
tissue pieces of the knee-joint capsule during meniscotomy. The
cells were isolated (8) and cultivated in Dulbecco's modified Eagle
medium supplemented with 100 g/l heat inactivated foetal calf
serum and 10 g/l antibiotic and antimycotic solution (containing
penicillin (lO5 U/l), streptomycin (100 mg/1) and amphotericin B
(2.5 mg/1)) in a humidified incubator with 5% CO2. Cells (lO8)
were incubated for 72 hours in 9 ml medium. The medium was
collected and the inhibitory activity of TFPI was determined.
Cloning synovial cells
The detailed techniques for cloning and characterising synovial
cells will be published elsewhere (10). In brief, to obtain homo-
geneous cell cultures of human synovial cells 100 μΐ of a diluted
cell solution were transferred to a well of a microtitre plate and
examined under a light microscope. Only wells containing a single
cell were used for further investigations. Cell culture medium was
' added and a polycarbonate filter (pore size 0.1 μηι) with an at-
tached monolayer of the same cell preparation was cocultivated.
The cells had no direct contact with the single cell and were neces-
sary for optimal growth of the isolated cell. The resulting human
synovial cell clones were incubated in cell culture medium, and
characterised by fibroblast-specific cell markers (chondroitin-6-sul-
Reverse transcription
Isolated RNA (0.1-5 μg) and 7 pm l oligo d(T)12_18 primer were
incubated at 37 °C for 90 min with 10 umol dNTP and 200 U
reverse tr nscriptase1) (12). The synthesised cDNA/RNA hybrids
were irnmediately used for the polyraerase chain reaction.
Tissue factor pathway inhibitor cDNA synthesis
A full-length cDNA was synthesised using the polymerase chain
reaction (13). The following primers were used (5):
primer I:
S'-TACTGCAGCGCCAAGAACTTTCATCAGAGA-^1;
primer II:
S'-GCGAATTCGCTAATGTTACATTGCTATAAC-S'
The cDNA complementary sequences of the primers are in bold
type. Primer I contains a Pst I l) restriction site and primer II an
Eco RI !) site.
Deoxyribonucleic acid sequencing
The endonuclease restriction sites, Pst I and Eco Rl, of the gener-
ated araplification product were used for cloning into the vector
" pUC 18. The TFPI coding DNA was C9nfirrned by double stranded
sequencing (14) in both upstreara an^downstreani orientation.
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Determination of tissue factor pathway inhibitor activity
The inhibitory activity of TFPI was measured by a modified
chromogenic Substrate assay based on the ability to inhibit factor
X activation by factor Vlla/tissue factor complex (15-17). Factor
VII (100 μΐ, 12.5 U/l) and 100 μΐ recombinant tissue factor (di-
lution: 1/20) were added to 100 μΐ 0.075 mol/1 CaCl2 and 100 μΐ
factor X (25 U/l). After 10 min incubation, 100 μΐ cell culture
medium (l : 5 diluted in 0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl, pH
8.0) were added and, after additional incubation for 10 min, vir-
tually all of factor X (400 U/l) was added in a volume of 100 μΐ.
After incubation for 10 min the chromogenic reaction was started
by the addition of 100 μΐ of the synthetic Substrate N-benzoyl-Ile-
Glu-Gly-Arg-jp-nitroanilide (0.0027 mol/1) and the absorbance was
measured at 405 nm. All samples were heat inactivated for 10 min
at 56 °C before testing.
Inhibition ofTFPI activity by anti-TFPI antibody
In the chromogenic Substrate assay for factor Xa activity the inhibi-
tory activity of tissue factor pathway inhibitor was suppressed by
a monospecific goat anti-TFPI antibody. The antibody was obtained
by immunisation of a goat with recombinant, two-domain TFPI
frorn yeast (18). Cell culture medium (100 μΐ, diluted l : 5 in 0.05
mol/1 Tris/HCl, 0.1 mol/1 NaCl, pH 8.0) was incubated with 100
ng anti-TFPI antibody for 30 min at room temperature. This di-
lution was used in the chromogenic Substrate assay s described
above.
Results
Isolation of TFPI-specific RNA and synthesis
ofTFPI cDNA
TFPI-specific DNA transcription products were isolated
from both human chondrocytes and human synovial
cells, and a TFPI coding cDNA of about 1000 b se pairs
was obtained by reverse transcription and polymerase
chain reaction (fig. 1). The gener ted TFPI cDNA was
Base
pairs
1018
516
Amplified DNA
958 base pairs
1 2 3 4
Fig. l Agarpse gel electroghoresis of reverse transcription-PCR
products of TFPI-specific miRNA.
The gel was stained with ethidiuna bromide.
Lane l and 4, DNA Standard;
lane 2, amplified DNA after reverse transeription and polymerase
chain reaction of mRNA isolated from human chondrocytes;
lane 3, amplified DNA after reverse transcription and polymerase
chain reaction of mRNA obtained frorn human synovial cells.
analysed by double stranded sequencing in both up-
stream and downstream orientation. No difference from
the TFPI coding nucleotide sequence described for hu-
man endothelial cells was observed.
After the Isolation of the total amount of RNA, an un-
specific cDNA synthesis was performed by reverse tran-
scription using an oligo-d(T)g-i2 primer. The syn-
thesised TFPI-specific RNA/cDNA hybrids were ampli-
fied by the polymerase chain reaction. The used primers
hybridised in the non-coding region close to the TFPI
coding sequence and gener ted the desired amplifi-
cation product.
The polymerase chain reaction primers I and II con-
tained single restriction sites (Pst l and Eco RI, respect-
ively) for cloning the amplified DNA into the vector
pUC 18. This vector was used for sequencing the ampli-
fied TFPI coding sequence.
Determination of the inhibi tory act ivi ty of
TFPI in cell culture medium
The inhibitory activity of TFPI in cell culture media
from human chondrocytes and cloned human synovial
cells was determined by measuring the Inhibition of fac-
tor X activation by factor Vlla/tissue factor complex,
using a synthetic Substrate (S-2222). The inhibitory ac-
tivity of TFPI in the medium of human synovial cells
was 1080-1665 mU/108 cells (n = 5). In the medium
of human chondrocytes the inhibitory activity was 630-
720 mU/108 cells (n = 3).
Inhibition ofTFPI activity by a monospecific
anti-TFPI-antibody
Hundred ng monospecific anti-TFPI antibody, specific
for the first two Kunitz domains of TFPI, quantitatively
suppressed the inhibitory activity ofTFPI in cell culture
media from human chondrocytes and human synovial
cells. In the chromogenic Substrate assay, factor X ac-
tivity was not infl enced by the addition of cell culture
medium preincubated with anti-TFPI antibody (fig. 2)
thus identiiying the inhibitory activity in the medium
s TFPI.
Disc ssion
The expression of tissue factor pathway inhibitor has so
far only been described for endothelial cells and mega-
karyocytes. We investigated the synthesis ofTFPI in hu-
man synovial cells and in human chondrocytes. Our in-
vestigations showed that these cells also synthesise
TFPIrspecific DNA transcription products and express
TFPI in the cell culture medium.
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Fig. 2 Effect of anti-TFPI antibody on the inhibitory activity of
tissue factor pathway inhibitor in cell culture media.
The amidolysis of the synthetic Substrate, N-benzoyl-Ile^GhnGly-
Arg-/?-nitroanilide, by factor Xa in the chromogenic assay was
monitored by measuring the absorbance at 405 nm. Factor Xa ac-
tivity was measured in the presence of (—A—) and without (—p—)
cell culture medium (20 ). Factor Xa activity was not influenced
by the addition of cell culture medium preincubated with 100 ng
anti-TFPI antibody (-^-).
The synthesis of tissue factor pathway inhibitor in hu-
man synovial cells and human chondrocytes seems to be
part of an important regulation process in the synovial
System, which maintains a balance between fibrinolytic
and clotting reactions during minimal bleeding, and a-
voids inadequate fibrin deposition on the cartiläge süf-
face of the joint.
Coagulation is initiated by tissue factor (thromboplastin)
which is expressed in fibroblasts, macrophages and en-
dothelial cells (19), and results in activation of the ex-
trinsic pathway of coagulation. Synovial cells are sup-
posed to lack tissue factor (20) which is necessary for
the extrinsic pathway of factor X activation. This hy-
pothesis has served äs an explanation for the special
joint bleeding in haemophiliacs. However, it was shown
that monocytes, which are present in the synovial mem-
brane, are able to produce tissue factor (20, 21) and
other procoagulant and anticoagulant molecules (22).
Whether synovial cells type A (23), which are probably
derived from monocytes, also synthesize tissue factor is
not known.
In haemophiliacs, factor Xa generation depends exclu-
sively on the factor Vlla/tissue factor pathway, since
factor VIII or factor IX are deficient. This deficieiicy
prevents an alternative activatioh of factor X. Thus, an
Inhibition of factor X activation by TFPI results in an
additional decrease in the coagulation process in haemo-
philiacs. It has been shown that the addition of TFPI in
a thromboplastin assay prolongs the coagulation time in
normal plasma, while the addition of an inhibitory anti-
body against TFPI shortens it (17, 18). Furthermore,
anti-TFPI antibody normalised the coagulation time in
haemophilic plasma in a dilute thromboplastin assay
(17). Therefore, the presence of TFPI in the synovial
System would seem to be the reason why joints are the
predilected site of bleeding in haemophiliacs. Ninety
percent of haemophilic bleeding occurs spontaneously
in the joints. Liberated plasma TFPI, in addition to TFPI
from synovial cells, represents an anticoagulant pöten-
tial which in haemophiliacs completely irihibits haemo-
stasis and leads to massive bleeding in the joints, even
when only small vessels are injured.
Further investigations will give mofe Information on the
physiological fiinction of TFPI in the synovial System
and on the influence of inflammatory mediators such äs
interleukin l, tumour necrosis factor and bacterial lipo-
polysaccharides on the cellulär expression of TFPI in
the synovium. These mediators are known to shift the
haemostatic balance in favor of procoagulant activities
in endothelial cells (24).
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